Our Approach

Publications


  • May 21, 2024

    Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

    Nature Communications Medicine

    Read Full Article »


  • January 15, 2024

    First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

    Nature Communications Medicine

    Read Full Article »